modelS02AA16
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Ofloxacin | |
| ATC code: | S02AA16 | route: | oral |
| compartments: | 1 | |
| dosage: | 400 | mg |
| volume of distribution: | 120 | L |
| clearance: | 14 | L/hr |
| other parameters in model implementation | ||
Ofloxacin is a second-generation fluoroquinolone antibiotic used for the treatment of a variety of bacterial infections, including respiratory tract infections, urinary tract infections, skin infections, and certain types of ear and eye infections. It is approved for human use and is included in various national and international formularies.
Pharmacokinetics
Pharmacokinetic parameters reported in healthy adult volunteers following single oral administration. Values reflect population mean estimates.
References
Jaruratanasirikul, S, et al., & Samaeng, M (2018). Population Pharmacokinetics and Pharmacodynamics Modeling of Oral Levofloxacin. Journal of the Medical Association of Thailand = Chotmaihet thangphaet 99(8) 886–892. PUBMED:https://pubmed.ncbi.nlm.nih.gov/29947489
Stambaugh, JJ, et al., & Peloquin, CA (2002). Ofloxacin population pharmacokinetics in patients with tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 6(6) 503–509. DOI:10.5588/09640569513011 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12068983
Zhang, J, et al., & Zhang, YY (2009). Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 15(5) 293–300. DOI:10.1007/s10156-009-0714-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19856067
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)